Senzer is a leader in the design and development of state-of-the-art respiratory devices for cancer care and the delivery of pharmaceutical cannabinoids

Our vision is to revolutionise the delivery of life-changing medicines and to become a vital partner to pharmaceutical companies throughout the world

Senzer has four key areas of activity. Our knowledge, capability and experience in these areas qualify the company as a trusted partner in the development and commercialisation of next-generation inhaler products. This enables Senzer to maximise value for its stakeholders and collaborative partners and bring significant medical benefit to patients and doctors.

  • Dedicated FDA and MHRA approved production facility in the UK with ISO 13485:2003 and ISO 9001:2008 accreditation.
  • State of the art ISO 7, class 10,000 cleanroom facilities, underpinned by a six sigma culture and GMP compliance.
  • Flexible supply chain with the ability to quickly adapt production for new or modified products currently manufacturing and exporting to the US market.
  • Quality-focused culture with a commitment to providing high quality, safe and effective medical devices.
  • Manufacturing in compliance with strict GMP, ISO 13485, FDA’s CFR Title 21 Part 820, and the EU’s Medical Device Directive 93/42/EEC.
  • A network of supporting regulatory experts with strong knowledge of medical devices, inhalers and cannabinoids.
  • Dedicated in-house team with extensive experience in product design and development.
  • In-house inhalation device testing capabilities for quick product development and refinement.
  • Deep inhalation device development experience across the business, including CEO who invented the underlying inhaler technology.
  • Ongoing focus on the development of new intellectual property, with extensive in-house and outsourced capabilities.
  • Focus on the development of strong cooperative relationships between Senzer and its commercialisation partners.
  • Extensive experience supporting partners in all aspects of clinical and regulatory development from early to late-stage development.
  • Developing a licencing model that will bring significant commercial benefit for all partners.